Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same
The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
1. An antibody that specifically binds to mesothelin (MSLN), comprising: a light chain variable domain (VL domain) comprising the amino acid sequence of SEQ ID NO: 1; and a heavy chain variable domain (VH domain) comprising the amino acid sequence of any one of SEQ ID NOs: 3 to 5.
2. The antibody of claim 1 , wherein the MSLN is human MSLN.
3. The antibody of claim 1 , wherein the antibody specifically binds to a mesothelin (MSLN)-expressing cancer cell.
4. The antibody of claim 3 , wherein the MSLN-expressing cancer cell is a human cancer cell.
5. The antibody of claim 1 , wherein the antibody is a humanized antibody.
6. A polynucleotide that encodes the light chain variable domain (VL domain) and the heavy chain variable domain (VH domain) of the antibody of claim 1 .
7. An expression vector comprising the polynucleotide of claim 6 .
8. A host cell transformed with the expression vector of claim 7 .
9. A method for producing an antibody that specifically binds to mesothelin (MSLN), comprising culturing the host cell of claim 8 .
10. A pharmaceutical composition comprising the antibody of claim 1 or an antigen-binding fragment thereof.
11. A method for treating cancer in a subject, comprising administering an effective amount of the antibody of claim 1 to the subject.
12. The method of claim 11 , wherein the cancer is mesothelioma, pancreatic cancer, ovarian cancer, gastric cancer, lung cancer, or endometrial cancer.
13. The method of claim 11 , wherein the antibody is a humanized antibody.